Self-Amplifying RNA Vaccines Give Equivalent Protection against Influenza to mRNA Vaccines but at Much Lower Doses

Murray, 2015, Global biogeography of human infectious diseases, Proc. Natl. Acad. Sci. USA, 112, 12746, 10.1073/pnas.1507442112 Tregoning, 2014, Using plasmids as DNA vaccines for infectious diseases, Microbiol. Spectr., 2, 2, 10.1128/microbiolspec.PLAS-0028-2014 Sahin, 2014, mRNA-based therapeutics--developing a new class of drugs, Nat. Rev. Drug Discov., 13, 759, 10.1038/nrd4278 Petsch, 2012, Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection, Nat. Biotechnol., 30, 1210, 10.1038/nbt.2436 Kuhn, 2010, Phosphorothioate cap analogs increase stability and translational efficiency of RNA vaccines in immature dendritic cells and induce superior immune responses in vivo, Gene Ther., 17, 961, 10.1038/gt.2010.52 Kowalska, 2014, Synthesis, properties, and biological activity of boranophosphate analogs of the mRNA cap: versatile tools for manipulation of therapeutically relevant cap-dependent processes, Nucleic Acids Res., 42, 10245, 10.1093/nar/gku757 Zhou, 1994, Self-replicating Semliki Forest virus RNA as recombinant vaccine, Vaccine, 12, 1510, 10.1016/0264-410X(94)90074-4 Dawood, 2012, Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study, Lancet Infect. Dis., 12, 687, 10.1016/S1473-3099(12)70121-4 2016, Role for migratory wild birds in the global spread of avian influenza H5N8, Science, 354, 213, 10.1126/science.aaf8852 Bahl, 2017, Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses, Mol. Ther., 25, 1316, 10.1016/j.ymthe.2017.03.035 Brazzoli, 2015, Induction of broad-based immunity and protective efficacy by self-amplifying mRNA vaccines encoding influenza virus hemagglutinin, J. Virol., 90, 332, 10.1128/JVI.01786-15 Démoulins, 2016, Polyethylenimine-based polyplex delivery of self-replicating RNA vaccines, Nanomedicine (Lond.), 12, 711, 10.1016/j.nano.2015.11.001 Shi, 2014, Enabling the ‘host jump’: structural determinants of receptor-binding specificity in influenza A viruses, Nat. Rev. Microbiol., 12, 822, 10.1038/nrmicro3362 Lin, 2012, Evolution of the receptor binding properties of the influenza A(H3N2) hemagglutinin, Proc. Natl. Acad. Sci. USA, 109, 21474, 10.1073/pnas.1218841110 Kinnear, 2015, A comparison of red fluorescent proteins to model DNA vaccine expression by whole animal in vivo imaging, PLoS ONE, 10, e0130375, 10.1371/journal.pone.0130375 Hekele, 2013, Rapidly produced SAM(®) vaccine against H7N9 influenza is immunogenic in mice, Emerg. Microbes Infect., 2, e52, 10.1038/emi.2013.54 Brito, 2014, A cationic nanoemulsion for the delivery of next-generation RNA vaccines, Mol. Ther., 22, 2118, 10.1038/mt.2014.133 Anderson, 2010, Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation, Nucleic Acids Res., 38, 5884, 10.1093/nar/gkq347 Karikó, 2005, Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA, Immunity, 23, 165, 10.1016/j.immuni.2005.06.008 Anderson, 2011, Nucleoside modifications in RNA limit activation of 2′-5′-oligoadenylate synthetase and increase resistance to cleavage by RNase L, Nucleic Acids Res., 39, 9329, 10.1093/nar/gkr586 Davis, 1996, In vitro activation of the interferon-induced, double-stranded RNA-dependent protein kinase PKR by RNA from the 3′ untranslated regions of human alpha-tropomyosin, Proc. Natl. Acad. Sci. USA, 93, 508, 10.1073/pnas.93.1.508 Kim, 2009, Original antigenic sin responses to influenza viruses, J Immunol., 183, 3294, 10.4049/jimmunol.0900398 Lambert, 2016, DNA vaccines encoding antigen targeted to MHC class II induce influenza-specific CD8(+) T cell responses, enabling faster resolution of influenza disease, Front. Immunol., 7, 321, 10.3389/fimmu.2016.00321 Nilsson, 2015, HIV-DNA given with or without intradermal electroporation is safe and highly immunogenic in healthy Swedish HIV-1 DNA/MVA vaccines: a phase I randomized trial, PLoS ONE, 10, e0131748, 10.1371/journal.pone.0131748 Cu, 2013, Enhanced delivery and potency of self-amplifying mRNA vaccines by electroporation in situ, Vaccines (Basel), 1, 367, 10.3390/vaccines1030367 Kalams, 2013, Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery, J. Infect. Dis., 208, 818, 10.1093/infdis/jit236 Pardi, 2017, Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination, Nature, 543, 248, 10.1038/nature21428 Pokrovskaya, 1994, In vitro transcription: preparative RNA yields in analytical scale reactions, Anal. Biochem., 220, 420, 10.1006/abio.1994.1360 Baillie, 2012, Evolutionary dynamics of local pandemic H1N1/2009 influenza virus lineages revealed by whole-genome analysis, J. Virol., 86, 11, 10.1128/JVI.05347-11 Elleman, 2004, The M1 matrix protein controls the filamentous phenotype of influenza A virus, Virology, 321, 144, 10.1016/j.virol.2003.12.009 Harker, 2007, Virally delivered cytokines alter the immune response to future lung infections, J. Virol., 81, 13105, 10.1128/JVI.01544-07